Vol. 26/No. 9

Benjamin P. Levy, MD, FASCO, discusses how new targeted approaches are affecting the NSCLC treatment landscape.

A panel of experts discusses the effort to personalize treatment approaches in metastatic castration-sensitive prostate cancer.

Sacituzumab tirumotecan plus pembrolizumab is currently being evaluated for select patients with TNBC in the phase 3 TroFuse-012 trial.

Maurie Markman, MD, details the lessons learned following results from older clinical trials within the oncology space.

GPC3 has the potential to be targeted in patients with HCC with reduced off-target toxicities compared with other targeted agents.

Lyudmila A. Bazhenova, MD, discusses the FDA approval of sunvozertinib (Zegfrovy) in patients with EGFR exon 20–mutant non–small cell lung cancer.

Results of an observational study showed that immunohistochemistry could act as a biomarker for the early detection of TP53‐mutant MDS or AML.

Shyam A. Patel, MD, PhD, and Jonathan M. Gerber, MD, discuss the next steps for validating IHC as a biomarker for TP53 mutations in MDS and AML.

Shyam A. Patel, MD, PhD, and Jonathan M. Gerber, MD, discuss the use of IHC testing for earlier identification of TP53 mutations in MDS and AML.

OncLive spoke with experts working to develop cellular therapies in solid tumors to gain insights into their current standing and future in the space.